US 12,377,068 B2
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
Jamie Singer, Knoxville, TN (US); Eric A. Wachter, Oak Ridge, TN (US); Satbir Thakur, Calgary (CA); Lucy Swift, Calgary (CA); Chunfen Zhang, Calgary (CA); Mohit Jain, Calgary (CA); and Aru Narendran, Calgary (CA)
Assigned to Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed by Provectus Pharmatech, Inc., Knoxville, TN (US); and UTI Limited Partnership, Calgary (CA)
Filed on Apr. 22, 2024, as Appl. No. 18/642,051.
Application 18/642,051 is a continuation of application No. 17/344,418, filed on Jun. 10, 2021, granted, now 11,974,980.
Application 17/344,418 is a continuation of application No. 16/412,872, filed on May 15, 2019, granted, now 11,058,664, issued on Jul. 13, 2021.
Claims priority of provisional application 62/672,373, filed on May 16, 2018.
Prior Publication US 2024/0277655 A1, Aug. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/343 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/343 (2013.01) [C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 45/06 (2013.01)] 6 Claims
 
1. A method of treating a pediatric cancerous solid tumor selected from one or more of the group consisting of Ewing sarcoma, neuroblastoma, osteosarcoma, neuroepithelioma, and rhabdomyosarcoma in a mammalian subject that comprises (1) intralesionally administering an amount of rose bengal or a pharmaceutically acceptable salt thereof that elicits ablation of tumor cells and (2) administering a tumor-inhibiting effective amount of one or more checkpoint inhibitor antibodies that binds with the PD-1 receptor, the PD-L1 receptor, or the CTLA-4 receptor.